Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03841435 · ClinicalTrials.gov registry record · NA
Hypofractionated Radiotherapy for Recurrent DIPG
A NA study, sponsored by University of Cincinnati.
- Completed
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT03841435 is a NA study that has completed, run by University of Cincinnati. The registered enrollment target is 5 participants.
The verdict
NCT03841435, a NA study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study evaluates the feasibility of hypofractionated radiotherapy (RT) in the palliative treatment of recurrent diffuse intrinsic pontine glioma (DIPG). Participants will receive 15 Gy in 3 fractions as opposed to the standard 20 Gy in 10 fractions.
Interventions
- RADIATION Hypofractionated Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-01-31 |
| Est. Completion | 2023-03-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03841435
The ClinicalTrials.gov registry entry for NCT03841435 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hypofractionated Radiotherapy is the first listed.
NCT03841435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03841435 about?
NCT03841435 is a clinical study titled "Hypofractionated Radiotherapy for Recurrent DIPG". This study evaluates the feasibility of hypofractionated radiotherapy (RT) in the palliative treatment of recurrent diffuse intrinsic pontine glioma (DIPG). Participants will receive 15 Gy in 3 fractions as opposed to the standard 20 Gy in 10 fractions.
What is the current status of trial NCT03841435?
This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2018-01-31. Estimated completion is 2023-03-03.
What interventions are being tested in trial NCT03841435?
The interventions under investigation include: Hypofractionated Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT03841435?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.